News

Light-activated crRNAs enable controlled CRISPR editing

A new strategy enables precise spatial and temporal control of CRISPR gene editing using chemically modified, photo-responsive guide RNAs. This approach allows selective activation of Cas9 and Cas12a editing systems via light exposure, achieving robust and tunable gene modulation in cells and in vivo.

By: Gorm Palmgren - Apr. 17, 2025
News

Chinese researchers have developed star-shaped, multivalent CRISPR RNAs (crRNAs) with single-site chemical modifications that include light-sensitive linkages. These modifications enable the crRNAs to remain inactive until irradiated with specific wavelengths of light, triggering rapid activation of gene editing without unintended background activity.

The system supports orthogonal control, meaning multiple gene targets can be regulated independently by using crRNAs responsive to different light wavelengths. In vitro assays showed minimal leakage in the inactive state and quick switching upon activation. Notably, the method demonstrated effective gene editing in mammalian cells in vivo, following brief photoactivation.

Because the crRNA design is independent of the target sequence, it avoids the need for extensive optimisation and is broadly compatible across CRISPR-Cas9 and Cas12a platforms. The authors suggest that future refinements using reversible and longer-wavelength responsive chemistries may improve tissue penetration and expand therapeutic potential.

The study was led by Liang Cheng at the Institute of Chemistry, Chinese Academy of Sciences in Beijing. It was published this Monday in Angewandte Chemie.

To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagNews

CLINICAL TRIALS
Multiple Sclerosis, (NCT07008378)
Sponsors:
Genentech, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Hemophilia B, (NCT06611436)
Sponsors:
Be Biopharma
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Heterozygous familial hypercholesterolemia, (ChiCTR2400093099)
Sponsors:
Primary sponsor: The First Affiliated Hospital of Bengbu Medical College Primary sponsor's address: 287 Changhuai Road, Longzihu District, Bengbu, Anhui, China Secondary sponsor: Country: China Province: Anhui City: Bengbu Institution hospital: The First Affiliated Hospital of Bengbu Medical College Address: 287 Changhuai Road, Longzihu District
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine